This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Gilead Sciences, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 10:30 AM
Transcript : Gilead Sciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM
Declaration of Voting Results by Gilead Sciences CI
Declaration of Voting Results by Gilead Sciences CI
Declaration of Voting Results by Gilead Sciences CI
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program CI
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates MT
UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating MT
Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75 MT
Maxim Adjusts Price Target on Gilead Sciences to $85 From $90 MT
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $117 From $120 MT
Barclays Adjusts Price Target on Gilead Sciences to $76 From $80 MT
TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 MT
Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95 MT
RBC Capital Adjusts Gilead Sciences' Price Target to $74 From $76 MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $78 From $80 MT
Gilead Sciences Receives FDA Approval for Updated Label of Biktarvy MT
Well, it isn't as bad as feared... Our Logo
Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV CI
News Highlights : Top Company News of the Day - Friday at 1 AM ET DJ
News Highlights : Top Company News of the Day - Thursday at 11 PM ET DJ
News Highlights : Top Company News of the Day - Thursday at 9 PM ET DJ
News Highlights : Top Company News of the Day - Thursday at 5 PM ET DJ
News Highlights : Top Company News of the Day - Thursday at 7 PM ET DJ
Gilead Sciences Q1 Tops Estimates, Updates Outlook MT
Chart Gilead Sciences, Inc.
More charts
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.29 USD
Average target price
82.93 USD
Spread / Average Target
+23.24%
Consensus
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. News Gilead Sciences, Inc.
  5. Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76